CHICAGO, March 11, 2014 /PRNewswire/ -- Medac
Pharma, Inc., a privately held pharmaceutical company focused on
the development of new molecules and improving the effectiveness of
existing medicines, announces the issuance, via its parent company,
medac GmbH, of U.S. patent 8,664,231 (the '231 patent) by the
United States Patent and Trademark Office. The patent,
entitled "Concentrated Methotrexate Solutions," is directed to a
method for the treatment of inflammatory autoimmune diseases by
subcutaneously administering methotrexate (MTX) at a concentration
of more than 30 mg/ml.
Medac Pharma and medac GmbH also announce the filing of a
lawsuit in the United States District Court in New Jersey against Antares Pharma, Inc.
(NASDAQ: ATRS), LEO Pharma A/S and LEO Pharma Inc. for infringement
of the '231 patent by their making, selling and offering for sale
of Otrexup™ (methotrexate) injection products for treating forms of
rheumatoid arthritis, polyarticular idiopathic arthritis and
psoriasis.
"The grant of the '231 patent in the U.S. is an important step
in our ongoing development of MPI-2505, which we believe has the
potential to be a best-in-class treatment option for rheumatoid
arthritis and psoriasis," said Ms. Terri
Shoemaker, President and CEO of Medac Pharma, Inc. "A
key advantage to MPI-2505 is its wide range of methotrexate dosing
options, which are designed to improve bioavailability and overcome
tolerability issues associated with today's oral methotrexate
therapies. Providing patients with a ready-to-use autopen for
the administration of MPI-2505 in reduced drug volumes also
addresses the stigmas associated with injectable medicines.
As such, the grant of the '231 patent is a significant event
for Medac Pharma, and we and our parent company, medac GmbH, plan
to vigorously defend and enforce it."
About Medac Pharma, Inc.
Medac Pharma, Inc. is the wholly-owned subsidiary of medac GmbH,
a well known and respected global pharmaceutical company that has
been making scientific and therapeutic discoveries for more than 40
years.
Medac Pharma, Inc. is focused on developing therapies with the
potential to make meaningful differences in patients' lives.
The company's approach is to improve existing agents by enhancing
the mode of delivery, addressing safety profiles and inventing ways
to maximize efficacy.
For more information, please visit www.medacpharma.com.
For Media:
Tiberend Strategic Advisors,
Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694
SOURCE Medac Pharma, Inc.